ClinicalTrials.gg
CompletedNCT00448383ReActUpdated Aug 4, 2008

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

A Phase 3 interventional study of adalimumab in Rheumatoid Arthritis, sponsored by Abbott. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-08-04.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,610
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
Largest of 87
6,610 · median 160
Started
2002
with 1 other
Phase 3
36 of 87
1 open now
Registered
17th of 87
by date
Lead sponsor
22 of 87
Abbott

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one has the largest enrollment, is one of 2 that started in 2002, is one of 36 in phase 3, and was the 17th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This is an open-label, multi-center study in which adalimumab (D2E7) is administered subcutaneously 40 mg every other week in addition to current anti-rheumatic therapies. Patients must have active disease despite standard anti-rheumatic therapy.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be 18 years or older
  • ACR criteria for diagnosis of RA for at least 3 months.
  • Active RA as defined by DAS28 >= 3.2 at study entry.
  • Unsatisfactory response or intolerance to prior DMARDs.
  • A negative pregnancy test (serum HCG) for women of prior to start of study treatment.
  • Use of reliable method of e.g. IUDs, condoms, or hormone (oral, implantable, or injectable) contraceptives by all female patients of childbearing potential. Male patients with procreative capacity should also ensure that effective contraception is used during the study and for 70 days after study completion

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with alkylating agents such as cyclophosphamide or chlorambucil.
  • Prior treatment with intravenous immunoglobulin or any agent within 30 days, or 5 half lives of the product, whichever is longer.
  • Prior treatment with investigational biologic therapy (e.g. anti CD4)
  • Treatment within the last 2 months with approved biologic therapy (eg etanercept, infliximab, anakinra)
  • Prior treatment with total lymphoid irradiation
  • History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma.
  • History of or current acute inflammatory joint disease of origin other than RA, e.g. mixed connective tissue disease, systemic lupus erythematosus etc.
  • History of uncontrolled diabetes, unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke (within 3 months) and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.
  • Positive serology for or C indicating active infection
  • History of positive status.
  • Persistent infection, or severe infections requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment.
  • Female subjects who are pregnant or breast-feeding.
  • History of drug or alcohol abuse in the last year.
  • Previous diagnosis or signs of demyelinating diseases
  • History of active tuberculosis (TB), histoplasmosis or listeriosis.
  • Signs of previous TB infection (chest X-ray signs or positive PPD skin test). The diagnosis of previous TB infection will be based on chest X-ray signs and on PPD skin test.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6,610 participants (actual)

Study arms

  • Experimental
    1

    Open-label adalimumab

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    40mg every other week

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Change of disease activity score (DAS28) compared with study entry

    Time frame: Week 12

  2. EULAR and ACR response criteria at week 12

    Time frame: Week 12

Secondary outcomes

  1. Adverse events

    Time frame: Baseline - Week 12

  2. Clinical laboratory parameters

    Time frame: Screening, Week 6 & Week 12 and/or ET

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23. PubMed 27338778 ↗
  • Burmester GR, Matucci-Cerinic M, Mariette X, Navarro-Blasco F, Kary S, Unnebrink K, Kupper H. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther. 2014 Jan 27;16(1):R24. doi: 10.1186/ar4452. PubMed 24460746 ↗
  • Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S, Kupper H. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum. 2008 Jan 15;59(1):32-41. doi: 10.1002/art.23247. PubMed 18163417 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002 and a primary completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2007
First posted
Mar 16, 2007
Start
Sep 2002
Primary completionActual
Nov 2004
Last update
Aug 4, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00448383
Lead sponsor
Abbott
First posted
Mar 16, 2007
Start date
Sep 2002
Primary completion
Nov 2004
Last update
Aug 4, 2008

Study contacts

Beverly Paperiello
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion